Internationale Partnersuche

Innovation & Technologie Angebot

Patented cell-free technology for production of active membrane proteins

Country of Origin: France
Reference Number: TOFR20180822001
Publication Date: 15 October 2018

Summary

A French Company in the field of production, purification, formulation and characterization of proteins has developed a patented process to produce functional membrane proteins stabilized in artificial liposomes forming proteoliposomes. This technology helps academics and pharmas in all their projects.The main advantage is speed and It can also produce a wide range of proteins.
Partnership can be considered via research or technical/commercial agreement agreement with technical assistance.

Description

Founded in 2011, the French Company is a French service provider or CRO (Contract Research Organisation), in the field of production, purification, formulation, and characterization of proteins.

The cell-free "technology" makes it possible to provide solutions to the main problems encountered with cellular expression: inclusion bodies, truncated proteins, unstable and cytotoxic proteins for example. From this technology, It is possible to express quickly and in quantity SIMPLE as DIFFICULT proteins. It can be membrane proteins in different formats: proteoliposomes, nanodiscs or solubilized. 

With the help of academic or private teams, this technology allows for example to provide membrane receptors which are then used to select biologic candidates by phage display.

Partnership can be considered via research or technical agreement or commercial agreement with technical assistance. For example :



Via research or technical agreement :

- Any partner able to bring a technology or know-how to serve the scaling-up of a cell-free system;



Via commercial agreement with technical assistance :

- Industrial partner interested in cell-free expression technology: developing combined offers to increase cell-free system expertise, working as subcontractors or industrial partners working through cell systems and want to expand their offer with the cell-free expression system.



Dependent on the results, the French company and the partner will develop together a proof of concept.



There are many applications such as vaccine development, antibody development, screening&diplay, in vitro diagnotics, structural biology and protein vectorization.

The French company is an expert for all these applications and allows you to focus on what matters for your projects development.

Advantages and Innovations

The first advantage is speed. Indeed, this technology allows a protein production in 1 or 2 days when an in vivo system will take weeks or even months for some proteins.

It can also produce a wide variety of proteins, from the simplest to the most complex.

Moreover, compared to a traditional cellular expression system, the cell-free one is an open system offering the advantage of being able to incorporate additives that influence transcription, translation and folding and thus finely modulate the synthesis of the protein of interest. This system thus makes it possible to produce proteins that it would not be possible to synthesize via cellular systems. (cytotoxic proteins, complex ones...).

The cell-free system developed by the company is based on E.coli bacterial extracts. It is the most widely used and has established itself for several reasons including large-scale fermentation at low costs and high production yields.

Stage Of Development

Already on the market

Stage Of Development Comment

scaling-up of the technology under development

Requested partner

Any partner able to bring a technology or know-how to serve the scaling-up of a cell-free system

Industrial partner interested in cell-free expression technology

Partner to apply at EU grant application

The French company will commission a commercial agreement with technical assistance or services agreement to express, purify, characterize the proteins. Dependent on the results, the French company and the partner will develop together a proof of concept.

Dissemination Countries

Belgium, Brazil, Canada, Switzerland, Germany, Spain, Finland, France, Israel, India, Italy, Japan, South Korea, Norway, Poland, Sweden, Singapore, United Kingdom, USA, Vietnam